EGFR and neoplasm: The activation of compensatory mechanisms under treatment leading to resistance and tumor regrowth is seen with many targeted therapies including HER2+ tumors treated with trastuzumab, HER1+ tumors treated with cetuximab, and for hormone-dependent tumors treated with endocrine therapies [23,28,47].